Sep. 29, 2014, 6:58 AM
- Tokyo-based Daiichi Sankyo Co. acquires San Diego-based Ambit Biosciences (NASDAQ:AMBI) for $15 per share ($410M) in cash plus as much as $4.50 per share in milestones.
- The deal gives Daiichi access to Ambit's late-stage experimental leukemia drug quizartinib.
- Daiichi's purchase price represents an 83% premium over Friday's $8.20 close.
Ambit Biosciences Corp is a biotechnology company. It is engaged in discovering, developing & commercializing small molecule therapeutics for the treatment of cancer.
Country: United States